Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 57 | Gilead SciencesINDUSTRY | 8 | Nov 19, 2018 | clinicaltrials |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 311 | Gilead SciencesINDUSTRY | 13 | Nov 19, 2018 |
| clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Bridalveil) | terminated | Phase 3 | 475 | Gilead SciencesINDUSTRY | 15 | Nov 16, 2018 | clinicaltrials |
| NCT00002835 | Combination Chemotherapy in Treating Patients With Lymphoma | completed | Phase 3 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00002565 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | completed | Phase 3 | 61 | M.D. Anderson Cancer CenterOTHER | 3 | Nov 14, 2018 | clinicaltrials |
| NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | completed | Phase 3 | 122 | Novartis PharmaceuticalsINDUSTRY | 17 | Nov 8, 2018 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03733340 | Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT | unknown | Phase 2 / Phase 3 | 250 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038090 | Thalidomide-Dexamethasone for Multiple Myeloma | completed | Phase 2 / Phase 3 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038233 | Thalidomide for Multiple Myeloma | completed | Phase 3 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038558 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | completed | Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038805 | Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | terminated | Phase 2 / Phase 3 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00641095 | Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma(MCLPIII) | completed | Phase 2 / Phase 3 | 370 | University College, LondonOTHER | 2 | Oct 31, 2018 | clinicaltrials |
| NCT03665480 | The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03701217 | Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML | unknown | Phase 2 / Phase 3 | 220 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01305655 | Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL(NOPHOCPG2) | completed | Phase 3 | 47 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Sep 28, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT00824993 | Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients | completed | Phase 3 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00332202 | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | completed | Phase 3 | 758 | Eli Lilly and CompanyINDUSTRY | 25 | Sep 10, 2018 | clinicaltrials |
| NCT02489500 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib(VelRand) | terminated | Phase 3 | 3 | Boston Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT01908621 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. | completed | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT03647072 | PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | recruiting | Phase 3 | 60 | Sherief Abd-ElsalamOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT00135499 | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma | terminated | Phase 3 | 138 | Lymphoma Study AssociationOTHER | 3 | Aug 23, 2018 | clinicaltrials |
| NCT03454945 | Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides | unknown | Phase 3 | 30 | Cairo UniversityOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT01191801 | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML(VALOR) | completed | Phase 3 | 711 | Sunesis PharmaceuticalsINDUSTRY | 15 | Aug 22, 2018 | clinicaltrials |
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00718549 | A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 128 | Hoffmann-La RocheINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT02635984 | Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens(FOND-O) | completed | Phase 3 | 108 | Augusta UniversityOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | terminated | Phase 2 / Phase 3 | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03623087 | SIMPLE Chemotherapy for NK Lymphoma/Leukaemia | unknown | Phase 3 | 68 | The University of Hong KongOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT01535391 | Nilotinib in PH+, BCR-, ABL+ CML Patients(CML0811) | completed | Phase 3 | 109 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT00232934 | Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients | completed | Phase 3 | 400 | Gruppo Italiano per lo Studio del Mieloma MultiploOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01237808 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | completed | Phase 3 | 144 | University of UlmOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01973387 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | completed | Phase 3 | 160 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 24, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT00056056 | Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides | terminated | Phase 3 | 93 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 9, 2018 | clinicaltrials |
| NCT00566228 | Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma | completed | Phase 3 | 122 | Mayo ClinicOTHER | 1 | Jul 9, 2018 | clinicaltrials |
| NCT01098656 | Lenalidomide Maintenance Post-debulking in Advanced CTCL | terminated | Phase 3 | 21 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 9, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | unknown | Phase 2 / Phase 3 | 70 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT03553537 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unknown | Phase 3 | 100 | Southwest Hospital, ChinaOTHER | 0 | Jun 12, 2018 | clinicaltrials |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients(Myeloma XI) | unknown | Phase 3 | 4,420 | University of LeedsOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT00656448 | A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | completed | Phase 3 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Nov 19, 2018source: clinicaltrials